Please login to the form below

Not currently logged in

Vikas Sinha joins Verona as non-executive director

Brings strong US and financial experience to the UK drug development firm

Verona Pharma Vikas SinhaUK drug development company Verona Pharma has appointed Vikas Sinha as a non-executive director.

Currently executive vice president and chief financial officer at Alexion Pharmaceuticals, Sinha has served at the rare disease firm since 2005.

Prior to that he spent 11 years at Bayer, holding roles in the US, Canada, Japan and Germany, latterly as chief financial officer for Bayer Pharmaceuticals Corporation in the US.

Dr David Ebsworth, chairman of Verona Pharma, said: “Vikas' impressive financial background, including his US expertise, makes him a very welcome addition to our Board of Directors. 

“I have known Vikas for many years having worked together at Bayer and hold his impressive track record in high regard. We are pleased that Vikas will be joining our Board at such a pivotal time, as we progress our lead asset, RPL554, into a phase IIb clinical trial programme.”

A potential first-in-class treatment for chronic obstructive pulmonary disease (COPD), Verona Pharma's RPL554 is being tested as a nebulised maintenance treatment for patients with moderate to severe disease.

13th September 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...